greeksoup/ stock research

Iradimed (IRMD) Q1 FY2026 earnings: revenue $22 million, up 12.7% on the year

Iradimed Corp. (IRMD) reported revenue of $22 million for Q1 FY2026, the quarter ended 31 March 2026, up 12.7% on the same quarter a year earlier. Net income was $6 million, up 24.1% on the year, and diluted earnings per share $0.45. The figures are the company's own, from the 10-Q it filed with the SEC on 1 May 2026.

Revenue$22 millionup 12.7%
Net income$6 millionup 24.1%
Diluted EPS$0.45
QuarterQ1 FY2026ended 31 March 2026

The quarter, against the one before and a year earlier

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Revenue22.022.719.5+12.7%
Cost of revenue5.25.74.7+10.7%
Gross profit16.817.014.8+13.3%
Gross margin76.5%75.1%76.1%
Research and development1.00.80.6+53.1%
Operating income7.27.15.4+33.2%
Operating margin32.9%31.3%27.8%
Pre-tax income7.87.85.9+30.7%
Income tax2.01.31.3+55.1%
Effective tax rate25.1%17.3%21.2%
Net income5.86.44.7+24.1%
Net margin26.5%28.4%24.0%
Diluted EPS$0.45$0.50$0.37+21.6%
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Operating cash flow8.35.94.3+93.1%
Capital expenditure0.40.33.7-89.1%
Free cash flow7.95.60.6+1226.4%
Free cash flow margin35.9%24.8%3.0%
Cash from investing-0.5-0.4-3.9n/a
Cash from financing-2.6-10.9-2.3n/a
Depreciation and amortisation0.50.40.2+134.4%
Share-based compensation0.70.70.8-17.2%
Dividends paid2.68.62.2+18.3%
Diluted shares, weighted13m13m13m+0.3%
Shares outstanding at period end13m13m13m+0.5%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Shareholders' equity98.594.690.1+9.4%
Debt0.00.0n/an/a
Other liabilities15.914.211.7+36.0%
Total liabilities and equity114109102+12.4%
Fixed assets24.223.920.4+18.9%
Intangible assets3.33.43.3+0.8%
Cash and equivalents56.451.250.3+12.0%
Receivables13.413.712.7+5.6%
Inventory11.911.610.6+12.6%
Other assets5.25.14.5+15.7%
Total assets114109102+12.4%

Questions

What was Iradimed's revenue in Q1 FY2026?

Iradimed (IRMD) reported revenue of $22 million for Q1 FY2026, the quarter ended 31 March 2026, up 12.7% on the same quarter a year earlier.

How much did Iradimed earn in Q1 FY2026?

Net income for Q1 FY2026 was $6 million, up 24.1% on the year, and diluted earnings per share $0.45.

When did Iradimed report Q1 FY2026 results?

Iradimed filed its 10-Q for the quarter ended 31 March 2026 with the SEC on 1 May 2026.

Quarterly results, the last 20 quarters

Q3 FY2021Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025 †Q2 FY2025 †Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue10.911.912.312.713.414.915.516.116.517.517.617.918.319.419.520.421.222.722.020.5
Cost of revenue2.52.62.92.62.93.63.83.93.74.04.23.94.14.64.74.54.75.75.25.3
Gross profit8.49.29.410.110.511.211.712.212.813.413.414.014.214.814.816.016.517.016.815.2
Gross margin77%78%76%80%79%75%76%76%78%77%76%78%77%76%76%78%78%75%77%74%
R&D0.50.50.50.70.50.60.81.00.50.73.80.80.6-2.40.60.90.70.81.00.7
Operating income3.13.13.14.24.14.34.05.05.95.24.75.65.85.85.46.86.87.17.26.4
Operating margin28%26%25%33%31%29%26%31%36%30%27%31%32%30%28%33%32%31%33%31%
Pre-tax income3.13.13.14.24.24.74.35.36.45.75.26.36.46.35.97.37.37.87.86.9
Tax rate17%-25%19%22%19%22%22%21%21%20%21%22%21%19%21%21%24%17%25%24%
Net income2.63.92.53.23.43.73.44.25.14.54.14.95.05.14.75.85.66.45.85.2
Net margin24%33%20%25%26%25%22%26%31%26%24%27%28%27%24%28%26%28%26%25%
Diluted EPS$0.20$0.31$0.20$0.26$0.27$0.29$0.27$0.33$0.40$0.36$0.32$0.38$0.40$0.40$0.37$0.45$0.43$0.50$0.45$0.41
Operating cash flow3.43.41.41.63.93.04.63.51.43.93.96.69.16.04.37.77.05.98.35.9
Capital expenditure0.20.10.20.20.20.36.40.20.30.50.31.13.82.83.72.61.10.30.40.2
Free cash flow3.23.31.21.53.72.8-1.73.31.13.43.65.55.33.20.65.15.85.67.95.8
Dividends paidn/an/a12.60.00.00.013.20.00.00.08.01.91.91.92.22.22.28.62.62.6
Shares outstanding12m13m13m13m13m13m13m13m13m13m13m13m13m13m13m13m13m13m13m13m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 31 March 2026, filed 1 May 2026: the filing.